| 14th week of 2009 patent applcation highlights part 43 |
| Patent application number | Title | Published |
|---|
| 20090088331 | INFLUENZA VIRUS NUCLEIC ACID MICROARRAY AND METHOD OF USE - The present invention relates generally to methods of detecting and identifying known and unknown viruses using hybridization microarrays to essentially all known influenza virus nucleotide sequences of at least one type that infect at least one species, the sequencing of nucleotides which hybridize to the microarrays and analysis of the hybridized sequences with existing databases, thus identifying existing or new subtypes of viruses. The present invention also relates to methods of use of the microarrays of the invention for the detection of influenza viruses, including variant influenza viruses. The method includes the use of a non-specific PCR amplification method to amplify sample nucleic acids. | 2009-04-02 |
| 20090088332 | Multiplex Digital Immuno-Sensing Using a Library of Photocleavable Mass Tags - This invention provides methods, compositions and kits for immunosensing using photocleavable mass tags. | 2009-04-02 |
| 20090088333 | TARGET MOLECULE EVALUATION METHOD AND APPARATUS - AC potential is applied between a substrate electrode provided on a substrate and a counter electrode, a sample is brought into contact with a probe molecule bound to the substrate electrode, and a fluorescent signal obtained from a fluorescent marker provided on the probe molecule is observed to evaluate a target molecule in the sample that has bound to the probe molecule, wherein the target molecule is evaluated by measuring a signal intensity and/or a signal amplitude. | 2009-04-02 |
| 20090088334 | METHOD OF HIGH SENSITIVE IMMUNOASSAY - An object of the present invention is to provide a method of high sensitive immunoassay using immunoagglutination reaction by antigen-antibody reaction for quantification of a biological substance. The present invention provides a method for assaying an antigen comprising assaying agglutination which is generated by contacting an antigen with a carrier on which antibodies are supported, wherein the carrier on which antibodies are supported comprises a plurality of types of monoclonal antibodies that recognize different epitopes of an antigen supported thereon via simultaneous sensitization to the carrier. | 2009-04-02 |
| 20090088335 | NUCLEIC ACID SEQUENCING BY SINGLE-BASE PRIMER EXTENSION - The present invention pertains to a method for determining a sequence of contiguous bases within a polynucleotide, the method relying on single-base primer extension using labeled dideoxynucleotide terminators. The primers are immobilized to solid supports (e.g. microspheres or two-dimensional arrays), allowing for the identification of the labeled terminator incorporated into each primer. | 2009-04-02 |
| 20090088336 | MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF - The present invention provides devices and systems for use at the point of care. The methods devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device are modular to allow for flexibility and robustness of use with the disclosed methods for a variety of medical applications. | 2009-04-02 |
| 20090088337 | RET-Based Analyte Detection - Compositions and methods for Resonance Energy Transfer (RET) Based Detection of analyte binding are provided. | 2009-04-02 |
| 20090088338 | MULTI-CHANNEL MICROARRAY APPARATUS AND METHODS - A multi-channel microarray reader has a light source carried by a first supporting stage, a second supporting stage having a plurality of reaction assembly receiving positions, each position to receive a reaction assembly, wherein each reaction assembly includes a reaction chamber and an optical substrate to support a microarray chip, and wherein the reaction chamber and the optical substrate encapsulate a buffer solution. The reader also includes an imaging sensor positioned to detect fluorescence emitted from a single microarray chip and a motion control module to position at least one of the first and second supporting stages to cause a selected microarray chip to receive energy emitted from the light source and to position the imaging sensor to receive fluorescence from that microarray chip. | 2009-04-02 |
| 20090088339 | IDENTIFICATION OF ACTIVATED RECEPTORS AND ION CHANNELS - The present invention related to methods and reagents for generating and using activating mutations of receptors and ion channels. | 2009-04-02 |
| 20090088340 | METHODS FOR PREDICTING THE REDUCTION/OXIDATION (REDOX) REACTION ACTIVITY OF METAL COMPLEXES - The presently disclosed subject matter relates to methods of predicting or measuring the reduction/oxidation (redox) reaction-related reactivity of a metal complex, particularly with respect to the ability of the metal complex to catalyze or inhibit the generation of reactive oxygen species (ROS) in vivo. The presently disclosed subject matter further relates to methods of screening and/or developing drug candidates that can mediate metal complex-catalyzed ROS generation. More particularly, the presently disclosed methods involve the use of probes having NMR active nuclei that can interact with paramagnetic metals in ways that can be easily detected by nuclear magnetic resonance (NMR) spectroscopy. | 2009-04-02 |
| 20090088341 | MULTIPLEX ASSAY METHOD FOR MIXED CELL POPULATIONS - Disclosed is an in vitro assay for evaluating cellular activity, in which a culture is provided that contains one or more histologically different isolated mammalian cell-line that stably and constitutively express fluorescent proteins having a different emission spectra. The culture is assessed for cellular activity by quantifying fluorescence or detecting a pattern of fluorescence from fluorescent proteins present in the culture. In some embodiments, the cellular activity of the cell-lines is assessed by determining one or more of the growth rate, migration potential, or tubule formation potential of the cell-lines using the quantified fluorescence or pattern of fluorescence. Also disclosed are cell-lines have been stably transfected with mammalian expression plasmids that constitutively express different fluorescent proteins. Kits for performing the disclosed assays, which include the disclosed fluorescent cell-lines, are also disclosed. | 2009-04-02 |
| 20090088342 | SYSTEM, APPARATUS AND METHOD FOR APPLYING MECHANICAL FORCE TO A MATERIAL - The present invention details the design and operation of a miniaturized device array in which a range of simultaneous mechanical forces are produced by a single external pressure source. The invention is primarily embodied in a microfabricated device arrays designed to rapidly probe biological cell response to various combinations of mechanical, chemical and extra-cellular matrix parameters in a high-throughput fashion. | 2009-04-02 |
| 20090088343 | METHOD OF PATTERNING AND PRODUCT(S) OBTAINED THEREFROM - The present invention provides a method of patterning, the method comprising the steps of: (a) providing a porous film; and (b) adding at least one structure to the porous film. The present invention also provides a patterned film prepared according to the method of the invention. The present invention also provides a method of preparing a porous film, and a porous film prepared according to the method of the invention. | 2009-04-02 |
| 20090088344 | Method Selecting Highly Specific Probes For HPV Genotype Analysis and the Probes Thereof - A method for selecting a highly specific probe among a predetermined range of nucleotide sequences comprises:
| 2009-04-02 |
| 20090088345 | NECESSARY AND SUFFICIENT REAGENT SETS FOR CHEMOGENOMIC ANALYSIS - The present invention discloses methods of data analysis directed to diagnostic development, and in particular the development of signatures for classifying chemogenomic data. The invention provides methods for identifying and functionally characterizing a “necessary” set of information rich variables. The invention also discloses methods for identifying a plurality of “sufficient” classifiers. The necessary set of variables may be incorporated into a single diagnostic device to provide simultaneous confirmation of a classification measurement with a plurality of independent classifiers. In the field of biological diagnostics, the invention may be used to provide a plurality of short lists of genes, referred to as “signatures” that are “sufficient” to carry out specific classification tasks such as predicting the activity and side effects of a compound in vivo. | 2009-04-02 |
| 20090088346 | NOVEL COLLECTION OF HCDR3 REGIONS AND USES THEREFOR - The present invention is directed to the preparation and use of a collection of antibody heavy chain complementarity determining region 3 (HCDR | 2009-04-02 |
| 20090088347 | Treatment Fluid with Non-Symmetrical Peroxide Breaker and Method - A treatment fluid composition for treating a subterranean formation penetrated by a wellbore is formed from an aqueous fluid, a hydratable polymer and a water-soluble, non-symmetrical, inorganic peroxide breaking agent, which is capable of undergoing heterolytical cleavage. A method of treating a subterranean formation penetrated by a wellbore may also be performed by forming a treatment fluid from an aqueous hydrated polymer solution. This is combined with a water-soluble, non-symmetrical, heterolytically cleavable inorganic peroxide breaking agent. The treating fluid is introduced into the formation. An optional crosslinking agent capable of crosslinking the polymer may also be included. | 2009-04-02 |
| 20090088348 | Settable compositions comprising cement kiln dust and swellable particles - A variety of methods and compositions are disclosed herein, including, in one embodiment, a method comprising: introducing a settable composition into a subterranean formation, wherein the settable composition comprises: a cementitious component comprising a hydraulic cement and cement kiln dust; a swellable particle; and water; and allowing the settable composition to set in the subterranean formation. Another embodiment comprises a settable composition comprising: a cementitious component comprising a hydraulic cement and cement kiln dust; a swellable particle; and water. | 2009-04-02 |
| 20090088349 | FUNCTIONAL FLUID COMPOSITION - The fluid compositions of the present invention include an glycol component that includes a mixture of glycols according the formula: | 2009-04-02 |
| 20090088350 | DETERGENT / ANTI-OXIDANT ADDITIVES FOR LUBRICANTS - A composition is disclosed that comprises the reaction product of an acidic organic compound, a boron compound, and a basic organic compound. The composition is useful as a detergent additive for lubricants and hydrocarbon fuels. | 2009-04-02 |
| 20090088351 | Production of Biofuels and Biolubricants From a Common Feedstock - The present invention is directed to methods and systems for processing triglyceride-containing, biologically-derived oils, wherein such processing comprises conversion of triglycerides to free fatty acids and the separation of these fatty acids by saturation type. Such separation by type enables the efficient preparation of both lubricants and transportation fuels from a common source using a single integrated method and/or system. | 2009-04-02 |
| 20090088352 | TRACTOR HYDRAULIC FLUID COMPOSITIONS AND PREPARATION THEREOF - A tractor hydraulic fluid composition is prepared from an isomerized base oil which: a) the product itself, its fraction, or feed originates from or is produced at some stage by isomerization of a waxy feed from a Fischer-Tropsch process (“Fischer-Tropsch derived base oils”); or b) made from a substantially paraffinic wax feed (“waxy feed”). In one embodiment, the tractor hydraulic fluid composition is characterized as having a reduced level of viscosity modifier in an amount of 0 to 10 wt. %, and a Brookfield viscosity at −35° C. of less than 70,000 mPa.s. | 2009-04-02 |
| 20090088353 | LUBRICATING GREASE COMPOSITION AND PREPARATION - A grease composition is prepared from an isomerized base oil having consecutive numbers of carbon atoms and less than 10 wt % naphthenic carbon by n-d-M and a kinematic viscosity at 100° C. equal to or greater than 10 mm | 2009-04-02 |
| 20090088354 | LUBRICATING GREASE COMPOSITION AND PREPARATION - A grease composition is prepared from an isomerized base oil having consecutive numbers of carbon atoms and less than 10 wt % naphthenic carbon by n-d-M; a kinematic viscosity at 100° C. of less than 10 mm | 2009-04-02 |
| 20090088355 | Gear Oil Compositions, Methods of Making and Using Thereof - A gear oil composition is provided. The composition comprises a synergistic blend of mineral oil base stock and polyalphaolefin (PAO) base stock for the oil composition to have a traction coefficient at a slide to roll ratio of 40 percent at 15 mm | 2009-04-02 |
| 20090088356 | Gear Oil Compositions, Methods of Making and Using Thereof - A gear oil composition is provided. The composition comprises a synergistic blend of mineral oil base stock and polyalphaolefin (PAO) base stock for the oil composition to have a traction coefficient at a slide to roll ratio of 40 percent at 15 mm | 2009-04-02 |
| 20090088357 | Device for fragrancing automatic dishwashers and for improving the pearl-off performace of the rinsing water during the drying phase - An agent for use in dishwashers, which enables the dishwasher to be fragranced during protracted operating intervals and simultaneously improves the pearl-off performance of the rinsing water during the drying cycle, and which has a solid, preferably granular, structure at normal temperatures. The agent can be produced by exclusive use of a solid fragrance known per se. The solid fragrance contains a carrier material which is made of fatty alcohol or a mixture containing fatty alcohol and which is solid at normal temperatures, and, dissolved therein, a fragrance which is liquid at normal temperatures. The solution is composed quantitatively of between 40 and 60% by weight of carrier material and between 60 and 40% by weight of fragrance. | 2009-04-02 |
| 20090088358 | NOVEL METHOD FOR IMPROVING THE FOAMING PROPERTIES OF CLEANSING AND/OR FOAMING FORMULATIONS FOR TOPICAL USE - A method for improving foaming properties of cleansing and/or foaming formulations, compositions, methods for preparing them, and preparation of the topical formulations containing them are described. The method consists in including, in these formulations, an effective amount of a polyol glycoside or of a mixture of polyol glycosides of formula (I) R | 2009-04-02 |
| 20090088359 | MALE HYGIENE WIPE - A rapidly dissolvable wipe for male groin and genital surfaces includes a thick, absorbent sheet comprised of water-dispersible materials that impart flushability. The wipe has length and width dimensions that substantially exceed the width of standard toilet paper on a roll, and a thickness that substantially exceeds the thickness of standard toilet paper, making the wipe better suited for maintaining cleanliness and excellent hygiene of male groin and genital surfaces. | 2009-04-02 |
| 20090088360 | Bath Treatment Compositions and Methods - The present disclosure is generally directed to a bath treatment kit. The bath treatment kit includes a first formulation and second formulation. The first formulation includes a rheology modifier, the rheology modifier being present in a liquid and capable of thickening an aqueous bath. The second formulation includes a deswelling agent, the deswelling agent capable of thinning an aqueous bath previously thickened by the rheology modifier. | 2009-04-02 |
| 20090088361 | CLEANING AGENT FOR SEMICONDUCTOR DEVICE AND CLEANING METHOD USING THE SAME - The present invention provides a cleaning agent for cleaning a semiconductor device having copper wiring on the surface thereof following a chemical mechanical polishing process in a production process of a semiconductor device, including a compound represented by the following formula (I): | 2009-04-02 |
| 20090088362 | Cleaning and/or treatment compositions - This invention relates to compositions comprising a xyloglucan conjugate and processes for making and using such compositions including the use of such compositions to clean and/or treat a situs. | 2009-04-02 |
| 20090088363 | LIQUID TREATMENT COMPOSITION - According to the present invention there is provided a pearlescent liquid treatment composition suitable for use as a laundry or hard surface cleaning composition comprising a pearlescent agent, said pearlescent agent having D0.99 volume particle size of less than 50 μm and is present in composition at a level of from 0.02% to 2.0% by weight of the composition. | 2009-04-02 |
| 20090088364 | Pharmaceutical composition useful for the treatment of invasive pulmonary aspergillosis - The present invention provides a pharmaceutical composition comprising purified human mannan-binding lectin (MBL) optionally along with carriers administered at a unit dose in the range of 1.0 μg-5.0 μg/20 kg body weight. Further, it also deals with a method and use thereof for the treatment of invasive pulmonary aspergillosis using said composition. | 2009-04-02 |
| 20090088365 | Biosynthetic Polypeptide Fusion Inhibitors - Modified biosynthetic polypeptide fusion inhibitors, methods for manufacturing, and uses thereof are provided. | 2009-04-02 |
| 20090088366 | NITROSATED AND NITROSYLATED PROSTAGLANDINS, COMPOSITIONS AND METHODS OF USE - The invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E | 2009-04-02 |
| 20090088367 | Treatment of Insulin Resistance/Metabolic Syndrome to Alleviate the Risks of Dementia - This invention relates to Applicant's discovery that Metabolic Syndrome, a cluster of disorders stemming from a resistance to insulin, contributes directly to dementia, particularly Alzheimer's disease. Applicant's invention includes a screening method to determine susceptibility and diagnosis of dementia based on the risk factors for Metabolic Syndrome. Applicant's invention further includes methods for the prevention or treatment of dementia and other neurological conditions based on (1) minimizing insulin resistance, thereby preventing excess biosynthesis of insulin; (2) modulating the activity of IDE such that insulin competes less efficiently with β-amyloid protein for the IDE; and (3) blocking the consequences of NMDA receptor activation, such as by minimizing the generation of NO and other harmful free radicals. | 2009-04-02 |
| 20090088368 | COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families. | 2009-04-02 |
| 20090088369 | GLP-1 AND METHODS FOR TREATING DIABETES - The present invention relates to use of GLP-1 or a related molecule having a GLP-effect for the manufacture of a medicament for preventing or treating diabetes in a mammal. The amount and timing of administration of said medicament are subsequently reduced to produce a “drug holiday.” Practice of the invention achieves effective therapy without continuous drug exposure and without continuous presence of therapeutic levels of the drug. The invention also discloses a method of treating diabetes and related disorders in a mammal by administering glucagon like peptide (GLP-1) or a related molecule having GLP-1 like effect and thereby providing a therapeutically effective amount of endogenous insulin. | 2009-04-02 |
| 20090088370 | Method for Improved Isolation of Recombinantly Produced Proteins - The present invention provides a method for increasing the yield of a protein produced by cultivating eukaryotic cells and adding an ionic substance to the culture medium prior to harvest of the protein. Suitable ionic substances are the salts of the Hofmeister series, amino acids and peptone. | 2009-04-02 |
| 20090088371 | COMBINATION THERAPY WITH SYK KINASE INHIBITOR - The invention encompasses methods of increasing platelet levels in a patient having or at risk for immune thrombocytopenia comprising co-administering a Syk kinase inhibitor and a thrombopoietin receptor agonist, and methods of treating thrombocytopenia comprising co-administering a Syk kinase inhibitor and a thrombopoietin receptor agonist to a patient in need thereof, as well as pharmaceutical compositions for use in these methods. | 2009-04-02 |
| 20090088372 | Novel Bioconjugates As Therapeutic Agent and Synthesis Thereof - The present disclosure relates to a novel enzymatic approach according to the invention using an unprecedented sortase-catalyzed transpeptidation reaction between a substrate comprising LPXTG peptide motif and biomolecules such as aminosugars, hydroxyamino acids, hydroxyamino acid esters, aminolipids, polyamines; nucleic acids or derivatives thereof, or any molecule having such moieties; or any compound having such moieties to obtain a bioconjugates useful for target delivery of a compound. The present disclosure provides bioconjugates obtained by the novel sortase catalysed transpeptidedation reaction. | 2009-04-02 |
| 20090088373 | USE OF COMPOSITIONS TO ENHANCE INNATE IMMUNE RESPONSE - The present invention discloses methods of using of compounds for the enhancement of the innate immune system of a patient. In particular, the active compounds of the present invention include at least one calcineurin inhibitor, mTOR inhibitor or non-immunosuppresive derivative, or a derivative, isomer, or pharmaceutically acceptable salt thereof; and optionally, at least one calciferol or LMW inhibitor, or a derivative, isomer, or pharmaceutically acceptable salt thereof. Pharmaceutical formulations comprising same are also disclosed. | 2009-04-02 |
| 20090088374 | NOVEL USE - The present invention relates generally to the use of PA126 polypeptides and polynucleotides for healing various wounds arising from different causes. | 2009-04-02 |
| 20090088375 | Human prolactin antagonist-angiogenesis inhibitor fusion proteins - A novel fusion protein, comprising a receptor-antagonizing domain and an angiogenesis inhibiting domain, characterized, for example, by its ability to block apoptosis and/or inhibit endocrine response, is useful in treating cancer. For example, a human prolactin antagonist-endostatin fusion protein combines apoptosis induction and angiogenesis inhibition to combat cancer. | 2009-04-02 |
| 20090088376 | DENDRIMER BASED COMPOSITIONS AND METHODS OF USING THE SAME - The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer based compositions and systems for use in disease diagnosis and therapy (e.g., cancer diagnosis and therapy). The compositions and systems comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and monitoring the response to therapy of a cell or tissue (e.g., a tumor). | 2009-04-02 |
| 20090088377 | CYSTEIC ACID DERIVATIVES OF ANTI-VIRAL PEPTIDES - This invention relates to C34 peptide derivatives having improved aqueous solubility that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory synctial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections. | 2009-04-02 |
| 20090088378 | LONG LASTING INHIBITORS OF VIRAL INFECTION - This invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory synctial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections. | 2009-04-02 |
| 20090088379 | RECONSTITUTED SURFACTANTS HAVING IMPROVED PROPERTIES - The present invention is directed to a reconstituted surfactant containing a lipid carrier, a polypeptide analog of the native surfactant protein SP-C, and a polypeptide comprising a sequence comprised of repeated units where each unit contains between 3 and 8 hydrophobic amino acid residues and one basic amino acid residue. The invention is also directed to the pharmaceutical compositions thereof and to its use for the prophylaxis and/or treatment of RDS and other respiratory disorders. | 2009-04-02 |
| 20090088380 | GHRH ANALOGS AND THERAPEUTIC USES THEREOF - Described herein are growth hormone-releasing hormone (GHRH) analogs and uses for such analogs. In some embodiments, growth hormone related diseases may be treated with one or more synthetic GHRH analogs of 29 amino acids or more, exhibiting concomitantly an increased resistance to proteolysis and high binding affinity to human GHRH receptor in in vitro studies, in comparison with human native GHRH (1-29)NH | 2009-04-02 |
| 20090088381 | COMPOSITIONS CONTAINING ANTI-HIV PEPTIDES AND METHODS FOR USE - Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. | 2009-04-02 |
| 20090088382 | Use of the cathelicidin LL-37 and derivatives therof for wound healing - Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37. | 2009-04-02 |
| 20090088383 | GH SECRETAGOGUES AND USES THEREOF - The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject. | 2009-04-02 |
| 20090088384 | Therapeutic Fibrin-Derived Peptides And Uses Thereof - The invention relates to peptides having the general formula (I), or a salt or amide thereof, wherein R | 2009-04-02 |
| 20090088385 | Antibodies that bind to BGS-4 - The present invention provides novel polynucleotides encoding BGS-4 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides of the present invention. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-4 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention. | 2009-04-02 |
| 20090088386 | AMYLOID FIBRILLOGENESIS-INHIBITING PEPTIDE - The present invention provides a peptide which functions as a mimic peptide of an amyloid β peptide and is capable of inhibiting the fibrillogenesis of an amyloid β peptide. The present invention relates to: an 8- to 30-amino acid residue peptide comprising an amino acid sequence represented by the following formula (I): | 2009-04-02 |
| 20090088387 | COMPOSITION FOR LONG-ACTING PEPTIDE ANALOGS - The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm) | 2009-04-02 |
| 20090088388 | Peptides for Use In Treating Obesity - Novel cyclic and linear peptides of the formula R | 2009-04-02 |
| 20090088389 | NOVEL X-CONOTOXIN PEPTIDES (-II) - An isolated, synthetic or recombinant χ-conotoxin peptide having the ability to inhibit neuronal amine transporter comprising the following sequence of amino acids: Cys Cys Gly Tyr Lys Leu Cys Xaa5 Xaa6 Cys, SEQ ID NO: 3, where Xaa5 and Xaa6 are independently absent or represent any amino acid residue except Cys; or a sequence in which Gly, Tyr, Lys or Leu are subject to conservative amino acid substitution or side chain modification with the proviso that the peptide is not Mr1A, Mr1B, Mar2, CMrV1A, Bn1.5, Mr1.3 or Au1.4; or a salt, ester, amide, prodrug or cyclised derivative thereof. | 2009-04-02 |
| 20090088390 | POLYPEPTIDE - The present invention provides a polypeptide inducing the production of an antibody in permucosal administration in the presence of no immunological adjuvant, a composition containing the polypeptide, and use thereof. The present invention solves the above object by providing a polypeptide inserted with a cell attachment motif of a cell adhesive molecule to the peptide which has an amino acid sequence of multiagretope type T cell epitope at the amino terminal side of an inserted linker peptide, and an amino acid sequence of a B cell epitope at the carboxyl terminal side of the inserted linker peptide, a composition containing the polypeptide, and use thereof. | 2009-04-02 |
| 20090088391 | Strains of Lactobacillus Helveticus which do not Ferment Lactose - The invention relates to novel strains of | 2009-04-02 |
| 20090088392 | TREATMENT OF MELANOMA - An immunomodulatory compound is administered to treat, prevent, inhibit, or reduce melanoma in a subject. | 2009-04-02 |
| 20090088393 | METHODS AND FORMULATIONS FOR CONVERTING INTRAVENOUS AND INJECTABLE DRUGS INTO ORAL DOSAGE FORMS - Oral dosage compositions for drugs normally given intravenously such as Paclitaxel, containing a plant sterol to enhance solubility and a small intestine efflux inhibitor to prevent P-glycoprotein from being a barrier to absorption. | 2009-04-02 |
| 20090088394 | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT - Methods and compositions are described for the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide for the increase of efflux transporter activity at blood-brain, blood-CSF and placental-maternal barriers to increase the efflux of drugs and other compounds from physiological compartments, including central nervous system and fetal compartments. | 2009-04-02 |
| 20090088395 | CLARITHROMYCIN OR SALT THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF PULMONARY DISEASE INDUCED BY DESTRUCTION OF PULMONARY ALVEOLI - For the purpose of treatment and/or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli resulting from smoking, air pollution, noxious gas, etc., there are provided, among others, a method of administering clarithromycin or a salt thereof to a mammal and a pharmaceutical composition comprising clarithromycin or a salt thereof. | 2009-04-02 |
| 20090088396 | Active substance combination for cosmetic preparations - A combination of active substances for cosmetic preparations contains hyaluronic acid and at least one of its derivatives. At least 10 percent by weight is used in long-chain form with a molecular weight of at least 1,000,000 daltons. At least 2 percent by weight is used in short-chain form with a molecular weight not more than 200,000 daltons. | 2009-04-02 |
| 20090088397 | INHIBITORS OF SECRETION OF HEPATITIS B VIRUS ANTIGENS FOR TREATMENT OF A CHRONIC HEPATITIS VIRUS - A pharmaceutical composition comprising an effective amount of a compound of formulas (I-III) and a pharmaceutically acceptable carrier. Methods for treating a hepatitis virus in a patient comprising administering an effective amount of the compound of formulas (I-III) are also presented. | 2009-04-02 |
| 20090088398 | RECOMBINANT ADENOVIRAL VECTORS AND METHODS OF USE - This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective.) | 2009-04-02 |
| 20090088399 | Use of Light Sensitive Genes - The invention relates to the use of a light-gated ion channel for the manufacture of a medicament for the treatment of blindness and a method for expressing said cell specific fashion, e.g. in ON-bipolar cells, ON-ganglion cells, or AII amacrine cells. | 2009-04-02 |
| 20090088400 | PROSTAGLANDIN E2 MODULATION AND USES THEREOF - Methods, uses, kits and products are described for the prognosis, diagnosis, prevention and treatment of myotronic dystrophy type 1 (DM1), and more particularly for the prognosis, diagnosis, prevention and treatment of the congenital form of myotronic dystrophy type 1 (cDM1), based on changes in/modulation of prostaglandin E | 2009-04-02 |
| 20090088401 | In-situ cancer autovaccination with intratumoral stabilized dsRNA viral mimic - An improved autovaccination method designed to prevent or treat various neoplastic diseases by inducing a systemic immune response against a tumor and its remote metastases, consisting of the induction of an immunogenic cell death in one or more targeted tumor sites with local radiation therapy, cryotherapy, heat, chemotherapy or various other treatments, followed by intratumoral/peritumoral injection of dsRNAs (poly-ICLC in particular) in the same tumor site. | 2009-04-02 |
| 20090088402 | NOVEL AGENT FOR INDUCING APOPTOSIS COMPRISING MSX1 OR A GENE ENCODING THE SAME AS AN ACTIVE INGREDIENT - The present invention relates to a novel use of Msx1 protein or a nucleotide encoding the same for inducing apoptosis. The Msx1 of the present invention induces apoptosis through direct interaction with p53 via a homeodomain and such interaction leads to increased stability, and/or nuclear localization of p53 in cells. The Msx1 or homeodomain thereof can be effectively used for the treatment of tumors, in which wild-type p53 protein has lost its function by some mechanism that inactivates p53 proteins. | 2009-04-02 |
| 20090088403 | A3 ADENOSINE RECEPTORS AS TARGETS FOR THE MODULATION OF CENTRAL SEROTONERGIC SIGNALING - The present invention relates to the use of adenosine type 3 receptor (A3R) modulators to modulate serotonin transporter (SERT) function in vivo. In particular, antagonists of A3R can be used to inhibit A3R-dependent upregulation of SERT, for example, as antidepressants. | 2009-04-02 |
| 20090088404 | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine - Extended release formulations of S-methyladenosylmethionine (SAMe) are provided, as are methods of treating various disorders using extended release SAMe formulations. The extended release formulations may be used to treat a variety of disorders, including liver disorders, psychiatric disorders and joint disorders. Thus, extended release SAMe formulations may be used to treat alcoholic liver disease, fatty liver disease, hepatitis, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, and depressive disorders such as depression (e.g. major clinical depression) and dysthymia. | 2009-04-02 |
| 20090088405 | Personal lubricants with built-in or accompanying odorant delivery systems - A personal lubricant paired with an odorant release device. | 2009-04-02 |
| 20090088406 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS - The present invention provides a pyrrolidine compound of General Formula (1) | 2009-04-02 |
| 20090088407 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP - The present invention provides compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein. | 2009-04-02 |
| 20090088408 | PHARMACEUTICAL COMPOSITIONS ON ANTICHOLINERGICS, CORTICOSTEROIDS AND BETAMIMETICS - The present invention relates to novel pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics, processes for preparing them and their use in the treatment of respiratory diseases. | 2009-04-02 |
| 20090088409 | SERUM BIOMARKERS FOR EARLY DETECTION OF ACUTE CELLULAR REJECTION - The present invention provides an improved method of diagnosing a subject having received an organ transplant with Acute Cellular Rejection (ACR). The method comprises obtaining a biological sample from the subject, detecting an amount of at least one protein indicative of ACR in the sample, and comparing the amount of the protein in the sample to a control, wherein a difference between the amount of the protein in the sample relative to the control indicates the subject has or is developing ACR. The difference can be an increase or a decrease. In one version the biological sample comprises a serum sample, and the transplanted organ is selected from a heart, kidney, liver, bone marrow, pancreas, eye, lung or skin. A kit and methods of treating a subject having an organ transplant for ACR and treating an immune suppressed subject are also provided. | 2009-04-02 |
| 20090088410 | METHODS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE DISEASES USING 4-(AMINO)-2-(2,6-DIOXO(3-PIPERIDYL)-ISOINDOLINE-1,3-DIONE IN COMBINATION WITH OTHER THERAPIES - Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, in combination with a second active agent. Particular second active agents are is prednisone, JAK1 inhibitor, JAK2 inhibitor, FLT3 inhibitor, BCL2 inhibitor, and HDAC inhibitor. | 2009-04-02 |
| 20090088411 | No-donating corticosteroid with improved pharmacokinetic, anti-inflammatory and vasodilatory properties - There are herein provided methods of treatment and nitric oxide donating compositions of matter for the treatment of respiratory diseases and associated conditions. | 2009-04-02 |
| 20090088412 | COMPOSITION FOR TREATING CANCER CELLS AND PREPARATION METHOD THEREOF - A composition for treating cancer cells and a preparation method therefore is provided. The composition includes novel withanolide compounds derived from a Solanaceae plant, which the novel withanolide compounds have the cytotoxicity to the cancer cells. | 2009-04-02 |
| 20090088413 | Pharmaceutical composition for topical application - A topical composition for treatment of contact dermatitis comprising a corticosteroid, one or more drying agents, such as zinc oxide and talc, an alcohol solvent, a humectant and a viscosity agent, such as bentonite. The humectant may be glycerin, and the carrier is water. | 2009-04-02 |
| 20090088414 | Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof - The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog. | 2009-04-02 |
| 20090088415 | Controlled release pharmaceutical compositions - A non-disintegrating, non-eroding, non-bioadhesive and non-swelling oral controlled release pharmaceutical composition and process for preparation of such compositions is provided which comprises at least one high dose water soluble active ingredient, at least one diluent, at least one binder, and a polymer system comprising of at least one release controlling polymer wherein the composition formulated into a suitable dosage form maintains its geometric shape even after the drug has diffused from the dosage form and provides the concentrations of active ingredient above effective levels for extended periods of time, optionally with other pharmaceutically acceptable excipients. The compositions preferably comprise antibiotic(s) as active ingredient, more preferably Amoxicillin or its pharmaceutically acceptable salts, hydrates, polymorphs, esters, and derivatives thereof, most preferably amoxicillin sodium, either alone or in combination with other antibiotic(s). Also described are controlled release compositions which provide an initial burst release of approximately 20%-40% of the active ingredient within one hour for achieving blood levels equivalent to minimum inhibitory concentration, while maintaining these levels for an extended period of time. | 2009-04-02 |
| 20090088416 | DEUTERIUM-ENRICHED LAPAQUISTAT - The present application describes deuterium-enriched lapaquistat, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-04-02 |
| 20090088417 | VANILLOID RECEPTOR ANTAGONIST FOR PREVENTION AND TREATMENT OF DRUG DEPENDENCE AND ADDICTION - Disclosed is a composition for preventing and treating harmful actions caused by drugs of abuse. More particularly, disclosed is a pharmaceutical composition effective for preventing or treating dependence and spontaneous movements by using a drug acting against the vanilloid receptor Capsazepine, which is used as a drug acting against the vanilloid receptor, shows an excellent effect of alleviating conditions of cocaine dependence and addition during the development and recurrence thereof. Administration of the drug acting against the vanilloid receptor provides important information in developing an agent for preventing and treating drug dependence and addiction. | 2009-04-02 |
| 20090088418 | 4-SUBSTITUTED QUINUCLIDINE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF - The present invention relates to compounds and formulations capable of affecting nicotinic acetylcholine receptors (nAChRs), for example, as modulators of specific nicotinic receptor subtypes (specifically, the alpha7 nAChR subtype). The present invention also relates to methods for treating a wide variety of conditions and disorders, particularly those associated with dysfunction of the central and autonomic nervous systems. | 2009-04-02 |
| 20090088419 | PYRIDYL ACETIC ACID COMPOUNDS - The present invention provides a compound represented by the formula (I): wherein R | 2009-04-02 |
| 20090088420 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS - Pharmacophore models to be used in drug design and discovery are provided. An in silico protocol and in vitro assays are presented. Compounds and their pharmaceutically acceptable salts with HIV-1 integrase inhibitory and anti-HIV activity and use thereof in the treatment of HIV/AIDS and related infections either alone or in combination with all the known antiretroviral therapeutics are described. | 2009-04-02 |
| 20090088421 | Intranasal Anti-Convulsive Compositions And Methods - Contemplated pharmaceutical compositions comprise a benzodiazepine anti-convulsive compound for intranasal administration in a single phase, multi-component solvent system with water content of at least 15 vol % and a benzodiazepine concentration of at least 30 mg/ml. It is noted that contrary to common expectation, the concentration of the anti-convulsive compound was increased by increasing water content in the multi-component solvent. Moreover, the anti-convulsive compound remained chemically stable and substantially completely dissolved over large periods of time. Thus, stable and highly concentrated spray formulations for intranasal administration could be prepared having sufficiently high concentrations of the anti-convulsive compounds that now allow single spray administration to achieve clinically relevant dosages. | 2009-04-02 |
| 20090088422 | 4-IMIDAZOLIN-2-ONE COMPOUNDS - The present invention relates to a compound of the formula [I]: | 2009-04-02 |
| 20090088423 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTIONS AND DISEASES ASSOCIATED THEREWITH - The invention features methods and compositions for treating bacterial infections. | 2009-04-02 |
| 20090088424 | METHODS AND COMPOSITIONS FOR CONTROLLING THE BIOAVAILABILITY OF POORLY SOLUBLE DRUGS - Provided are methods and compositions for controlling the bioavailability of poorly soluble drugs, including, for example, efravirenz. | 2009-04-02 |
| 20090088425 | GLUCOCORTICOID RECEPTOR ANTAGONISTS - The present invention relates to compounds of formula I | 2009-04-02 |
| 20090088426 | Substituted 4-Phenyl Piperidines for Use as Renin Inhibitors - Compounds of the general formula (I) and the salts thereof, preferably the pharmaceutically acceptable salts thereof; in which R | 2009-04-02 |
| 20090088427 | Treatment of Vascular, Autoimmune and Inflammatory Diseases Using Low Dosages of IMPDH Inhibitors - The disclosure provides methods and compositions for treating a vascular, autoimmune, and/or inflammatory disease, or a condition associated therewith, with a dose of an inosine monophosphate dehydrogenase (IMPDH) inhibitor effective to treat the vascular, autoimmune and/or inflammatory disease, or associated condition but that does not produce immunosuppression sufficient to reduce the risk of allograft rejection. These lower doses of the immunosuppressant avoid the adverse consequences of severe immunosuppression while providing effective treatment of the vascular, autoimmune and/or inflammatory disease. | 2009-04-02 |
| 20090088428 | CYCLOHEXYLIMIDIAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 - The present invention discloses novel compounds of Formula I: (I) having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11β-HSD type 1 activity. | 2009-04-02 |
| 20090088429 | Isoquinoline Derivatives - The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I) | 2009-04-02 |
| 20090088430 | PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 - The present invention discloses novel compounds of Formula I: | 2009-04-02 |
